checkAd

     498  0 Kommentare Prostate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com

    PUNE, India, June 23, 2017 /PRNewswire/ --

    RnRMarketResearch.com added Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Pipeline Review H1 2017 research reports that provides comprehensive information on the Prostate Specific Antigentargeted therapeutics, complete with analysis by indications, stage of development and molecule type.

    Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2017 reviews key players involved, targeted therapeutics development with respective active and dormant or discontinued projects. Prostate Specific Antigen Pipeline is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

    Companies discussed in this report include: Advaxis Inc, Aeterna Zentaris Inc, Bavarian Nordic A/S, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, OncBioMune Pharmaceuticals Inc.

    Drugs profile discussed in this report include: ADXS-PSA, AEZS-120, Cellular Immunotherapy to Target PSA for Prostate Cancer, Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer, G-114, G-115, INO-5150, Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer, Monoclonl Antibody to Inhibit PSA for Prostate Cancer, Prostatac.

    Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=1082616 .

    Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Seite 1 von 2


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Prostate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com PUNE, India, June 23, 2017 /PRNewswire/ - RnRMarketResearch.com added Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Pipeline Review H1 2017 research reports that provides …